| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.77, 1.10] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.35 [1.12, 1.63] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.53 [0.39, 0.74] | | > 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-5) | 0.38 [0.26, 0.54] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 3.49 [1.61, 7.56] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.85 [0.56, 1.29] | | < 1 | | 0% | 1 study (1/-) | 77.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.39 [0.26, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.08 [0.04, 0.14] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.08 [0.05, 0.12] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.13 [0.16, 8.10] | | < 1 | | 0% | 1 study (1/-) | 45.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.13 [0.02, 57.26] | | < 1 | | 0% | 1 study (1/-) | 47.6 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.02 [0.01, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.12 [0.02, 0.98] | | < 1 | | 0% | 1 study (1/-) | 97.6 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 4.58 [0.51, 41.18] | | < 1 | | 0% | 1 study (1/-) | 8.9 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.13 [0.16, 8.10] | | < 1 | | 0% | 1 study (1/-) | 45.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.38 [0.04, 3.63] | | < 1 | | 0% | 1 study (1/-) | 80.0 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 2.27 [0.08, 67.88] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.90 [0.24, 3.40] | | < 1 | | 0% | 1 study (1/-) | 55.9 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.50 [0.15, 1.63] | | < 1 | | 0% | 1 study (1/-) | 87.5 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.27 [0.08, 67.88] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.13 [0.02, 57.26] | | < 1 | | 0% | 1 study (1/-) | 47.6 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.27 [0.08, 67.88] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.27 [0.08, 67.88] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.01 [0.00, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.13 [0.02, 57.26] | | < 1 | | 0% | 1 study (1/-) | 47.6 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 1.13 [0.02, 57.26] | | < 1 | | 0% | 1 study (1/-) | 47.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.28 [0.06, 1.32] | | < 1 | | 0% | 1 study (1/-) | 94.6 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 2.27 [0.08, 67.88] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.00 [0.00, 0.07] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 4.55 [0.20, 101.37] | | < 1 | | 0% | 1 study (1/-) | 17.2 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.58 [0.51, 41.18] | | < 1 | | 0% | 1 study (1/-) | 8.9 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 1.13 [0.02, 57.26] | | < 1 | | 0% | 1 study (1/-) | 47.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.57 [0.02, 16.92] | | < 1 | | 0% | 1 study (1/-) | 62.7 % | NA | not evaluable | | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 1.13 [0.02, 57.26] | | < 1 | | 0% | 1 study (1/-) | 47.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.13 [0.16, 8.10] | | < 1 | | 0% | 1 study (1/-) | 45.1 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.02 [0.00, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 2.27 [0.08, 67.88] | | < 1 | | 0% | 1 study (1/-) | 32.1 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.14 [0.02, 1.12] | | < 1 | | 0% | 1 study (1/-) | 96.8 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
